SNY May 2024 50.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:43AM EDT. Market open.
| Previous close | 1.0000 |
| Open | 0.4000 |
| Bid | 0.4500 |
| Ask | 0.6000 |
| Strike | 50.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.4000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 250 |
ZacksSanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
GuruFocus.comFulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
Comprehensive Analysis of Fulcrum Therapeutics' Financial Performance and Future Outlook
GlobeNewswireFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeut
© 2024 Yahoo. All rights reserved.